[Limerick, Ireland – September 2nd 2025] Today, Johnson & Johnson announces the launch of two new products to meet the evolving needs of astigmatic patients in Europe and the Middle East – ACUVUE® OASYS MAX 1-Day Contact Lenses for Astigmatism – the first contact lens to optimise toric design according to cylinder power,*2 and ACUVUE® OASYS MAX 1-Day MULTIFOCAL for Astigmatism – the first and only daily disposable multifocal toric contact lens for astigmatic presbyopes.^^,4Designed to address the evolving needs of astigmatic patients, both lenses offer exceptional comfort,+**2,3 clarity+2,3 and stability3,5 plus crisp, clear vision at all distances and in all lighting conditions for presbyopes.***3 Availability in the region will begin in select countries this September, with a further rollout in the following months.
Astigmatism affects about half of patients in at least one eye, making it one of the most common vision conditions.6 At the same time, it’s estimated that up to 2.1 billion people globally will develop presbyopia by 2030 due to our ageing population.7 While a variety of contact lens options exist for astigmatic patients, many still face challenges – with one in four discontinuing lens wear in the first year due to issues such as blurred or poor vision and discomfort.8 These challenges are even more pronounced for patients who develop both astigmatism and presbyopia, where contact lens options remain especially limited.¶9
"We see a clear unmet need in astigmatism and presbyopia across the region,9 and our goal has been to grow our ACUVUE® OASYS MAX 1-Day portfolio to address it. With the launch of these two new toric contact lenses in the region, we’re proud to offer the first and only complete family of daily disposable contact lenses.^^,###,4 This reflects our deep commitment to delivering tailored solutions that provide all-day comfort, clarity and stability for patients as they navigate an increasingly digitally-demanding world, while empowering eye care professionals with a comprehensive set of tools to meet their patients’ evolving needs," said Jacqueline Henderson, President Vision EMEA, Johnson & Johnson.
Next-Generation Innovation Tailored for the Astigmatic Eye
Both contact lenses have been developed with a patient-centric design,*5,14 enabling eye care professionals to provide more tailored solutions for astigmatic patients. The enhanced designs, supported by ACUVUE’s trusted Eye Inspired Innovations,¥Ϫ10 offer exceptional comfort,+**2,3 clarity+2,3 and stability3,5 for patients. Clinical data shows promising fit performance, with 99% first lens fit success for ACUVUE® OASYS MAX 1-Day for Astigmatism,∫∫,11 and 93% of wearers successfully fit within two pairs of lenses with ACUVUE® OASYS MAX 1-Day MULTIFOCAL for Astigmatism.***, 12 The efficient and streamlined fitting process may support more proactive fitting strategies, helping eye care professionals introduce optimal lens options earlier in the consultation process that could better match patients’ visual and lifestyle needs.
"Many of my patients with astigmatism struggle with finding a contact lens that works for them with limited options not addressing their needs – whether they’re looking for a high-performing daily disposable lens for their astigmatism or navigating the added complexity of presbyopia”, said Preete Kumar, Professional Affairs Consultant, Johnson & Johnson. “These new innovations from ACUVUE® offer tailored solutions for both groups, allowing me to meet my patients’ evolving vision needs without compromise. It’s a meaningful step forward in delivering more customised, consistent care.”
ACUVUE® OASYS MAX 1-Day for Astigmatism
Featuring a combination of 3 powerful technologies,^5 this contact lens delivers exceptional comfort, clarity+2 and stability,5 with enhanced stability for high cylinder patients.5 It has also shown proven performance across its key claims:,2
- 96% of patients reporting stable vision+,2
- Nearly 99% of patients reporting clear and reliable vision∫,2
- 89% of patients report all-day comfortπ,2
ACUVUE® OASYS MAX 1-Day MULTIFOCAL for Astigmatism
This first and only multifocal toric contact lens^^4 delivers crisp, clear vision at all distances and in all lighting conditions, in addition to all-day comfort and exceptional stability.***,3 The combination of 4 powerful technologies13 shows proven performance across its key claims for clarity, stability and comfort:***,3
- 95% of patients report clear vision during daily activities***,3
- Patients report 100% rotational stability ≤ 5 degrees with blink##,3
- 92% of patients report comfort throughout the day and at end-of-day***,≠,3
With the introduction of these new lenses in Europe and the Middle East, the ACUVUE® OASYS MAX 1-Day Family of lenses will be the first and only comprehensive family of daily disposable contact lenses in the region.^^,###,4 ACUVUE® OASYS MAX 1-Day lenses will now be available in spherical, toric, multifocal, and multifocal toric designs, providing coverage for more than 96% of eyes.###,13
ACUVUE® OASYS MAX 1-Day for Astigmatism will be available in Italy, the United Kingdom, Ireland, Germany, Austria, Switzerland, France, the Nordics, Poland, Türkiye and GCC in 2025. ACUVUE® OASYS MAX 1-Day MULTIFOCAL for Astigmatism will be available in Italy, France and the Nordics in 2025. Both lenses will continue to be rolled out in additional countries in Europe and the Middle East throughout 2026.
+++
About Vision at Johnson & Johnson
Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients’ eyes. We have a bold ambition: Vision Made Possible – improving sight for more than 40 million people each year. Through cutting-edge innovation, expertise in material and optical science, and advanced technologies, we are revolutionising the way people see and experience the world. Visit us at clearvisionforyou.com, follow @JNJVision on Twitter, Johnson & Johnson | Vision on LinkedIn, and @JNJVision on Facebook.
About Johnson & Johnson MedTech
At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalised.
Important Safety Information: ACUVUE® Contact Lenses are indicated for vision correction. As with any contact lens, eye problems, including corneal ulcers, can develop. Some wearers may experience mild irritation, itching or discomfort. Contact lenses should not be used in case of eye infections or any other eye conditions, or in case of a systemic disease that may affect the eye. For detailed product information, including contraindications, precautions and adverse reactions, please consult the Instructions for Use available on Johnson & Johnson website www.e-ifu.com
For any additional information, please visit our Johnson & Johnson Vision website https://www.jnjvisionpro.co.uk
Cautions Concerning Forward-Looking Statements:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to ACUVUE® OASYS MAX 1-Day Contact Lenses for Astigmatism. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.